Cue Biopharma reported that its chronic hives candidate cleared a Phase 2 study in China, achieving the trial’s primary endpoint in chronic spontaneous urticaria. The readout marks the company’s first clinical data since pivoting from oncology into immunology, positioning the asset as a potential Xolair challenger. The biotech said the Phase 2 results support moving the program into a Phase 2b/3 trial, aiming to confirm efficacy and further characterize safety in a larger population. Chronic spontaneous urticaria remains a competitive space, with established biologics setting the bar for sustained symptom control. For Cue, the milestone is also a credibility reset after strategic changes, as it reframes its pipeline around immunology rather than cancer targets.